- Investing Ideas
- U.S. Pharmaceuticals & Biotech Buy the Dip
U.S. Pharmaceuticals & Biotech Buy the Dip
Results
6
Companies which have seen a dip in the last 7 days after continued gains and are looking undervalued based on Snowflake checks.
6 companies
Madrigal Pharmaceuticals
Market Cap: US$12.6b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$493.11
7D
-9.2%
1Y
63.0%
Canton Strategic Holdings
Market Cap: US$148.8m
Engages in the institutional blockchain adoption and digitization of financial markets in the United States.
CNTN
US$1.85
7D
-10.2%
1Y
48.6%
Cue Biopharma
Market Cap: US$117.7m
A clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders.
CUE
US$30.40
7D
-8.1%
1Y
35.0%
Apollomics
Market Cap: US$38.4m
A clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.
APLM
US$17.35
7D
-8.0%
1Y
198.1%
Polyrizon
Market Cap: US$21.7m
A biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.
PLRZ
US$11.62
7D
-20.8%
1Y
77.7%
Galera Therapeutics
Market Cap: US$16.2m
A biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer.
GRTX.D
US$15.62
7D
-10.7%
1Y
239.6%